<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626574</url>
  </required_header>
  <id_info>
    <org_study_id>105838c</org_study_id>
    <secondary_id>USF 6176-P67638</secondary_id>
    <nct_id>NCT00626574</nct_id>
  </id_info>
  <brief_title>Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa</brief_title>
  <acronym>EPO</acronym>
  <official_title>A Double Blinded, Placebo Controlled, Pilot Study to Evaluate the Safety of Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blinded, placebo controlled pilot safety study that
      will enroll a total of twenty subjects. Subjects will be adults (30-75) who have sustained a
      SAH secondary to cerebral aneurysm rupture and who present with minimal neurological
      symptoms. All subjects will have a Hemoglobin less than or equal to 12 g/dL within 24 hours
      prior to study entry and undergo operative aneurismal clipping. Subjects will be randomized
      into two groups, ten subjects receiving the drug and ten subjects receiving the placebo. The
      subjects will receive three intravenous injections of study drug or placebo, once before
      undergoing operative aneurysmal clipping (study Day 1) and again for two additional days
      (study Day 2 and study Day 3).

      There are 3 phases to this trial:

      Screening Phase - patients will present with Subarachnoid hemorrhage (SAH) and prepped for
      surgery within 36 hours Treatment Phase - first pre-operative dose before surgery (Study Day
      1), post-operative (Study Days 2 and 3) Follow-up Phase- Study Day 4 through discharge, 6-7
      week follow-up Primary Objective: To determine the safety of administering intravenous doses
      of Procrit® once daily for three consecutive days to patients with aneurysmal SAH before and
      after vascular clipping by comparing the incidence of thrombotic events, hemoglobin and 6-7
      week mortality between the Procrit® and placebo groups. Secondary Objectives: To determine if
      administration of Procrit® prior to aneurysm clipping reduces the incidence of vasospasm
      following a SAH event treated by vascular clipping. To determine if Procrit® administration
      prior to aneurysm clipping in patients with Aneurysmal SAH will improve neurological
      assessment scores in the post-SAH/post-clipping time period. To determine the feasibility of
      organizing a larger, randomized study to explore the neuroprotective effect of Procrit® in
      patients with Aneurysmal SubArachnoid Hemorrhage (SAH) when Procrit® is administered prior to
      surgical clipping of the aneurysm.

      It is hypothesized that Procrit will provide a significant level of neuroprotection in the
      brain after an SAH event as a result of reduced cell death, as well as a reduced amount of
      vasospasm activity and delayed cerebral ischemia which can occur as a result of SAH. These
      factors may contribute to improved neurological functioning scores when compared to the
      placebo treated patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study is terminated as a result of data from a study that showed increased mortality in
    stroke patients.
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events After Administering Intravenous Doses of Procrit® Once Daily for Three Consecutive Days to Patients With Aneurysmal SAH Before and After Vascular Clipping</measure>
    <time_frame>First 10 days following clipping and 6 week F/U</time_frame>
    <description>Number of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine if Administration of Procrit® Prior to Aneurysm Clipping Reduces the Incidence of Vasospasm Following a SAH Event Treated by Vascular Clipping.</measure>
    <time_frame>first 10 days following clipping and 6 week f/u</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine if Procrit® Administration Prior to Aneurysm Clipping in Patients With Aneurysmal SAH Will Improve Neurological Assessment Scores in the Post-SAH/Post-clipping Time Period</measure>
    <time_frame>First 10 days following clipping and 6 week f/u</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Feasibility of Organizing a Larger, Randomized Study to Explore the Neuroprotective Effect of Procrit® in Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) When Procrit® is Administered Prior to Surgical Clipping of the Aneurysm.</measure>
    <time_frame>When all data is collected and analyzed</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
    <description>Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Procrit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 30-75

          -  Patients undergoing vascular clipping post SAH

          -  Aneurysmal SAH as determined by history or clinical evaluation

          -  WFNS Score I and II

          -  Hb ≤ 12 g/dL within 36 hours prior to first dose of study drug

          -  Patients who receive Study drug and undergo surgical clipping of the aneurysm within
             36 hours of the SAH event

        Exclusion Criteria:

          -  Non-aneurysmal SAH

          -  WFNS Score III and higher

          -  Patients presenting with previous history of SAH

          -  Terminal, brain-dead, comfort care patients

          -  Patients not undergoing vascular clipping

          -  Hb &gt; 12 g/dL

          -  Patients receiving blood transfusion prior to surgery

          -  Patients who currently receive Procrit or an EPO product

          -  Patients undergoing surgical clipping of the aneurysm greater than 36 hours after the
             SAH event

          -  Pregnancy or lactating

          -  Renal insufficiency (must present and maintain normal creatinine levels)

          -  Uncontrolled hypertension (systolic &gt; 150 mmHg)

          -  Active or known seizure history within one year of SAH event

          -  Known history of thrombotic vascular events (PE, DVT, AMI, stroke)

          -  Allergy or sensitivity to mammalian derived products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrico M Camporesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>September 8, 2011</results_first_submitted>
  <results_first_submitted_qc>September 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2012</results_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Enrico Camporesi</investigator_full_name>
    <investigator_title>Emeritus Professor, Dept of Surgery</investigator_title>
  </responsible_party>
  <keyword>Epoetin alfa</keyword>
  <keyword>aneurysm</keyword>
  <keyword>subarachnoid hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Procrit</title>
          <description>Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Procrit</title>
          <description>Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events After Administering Intravenous Doses of Procrit® Once Daily for Three Consecutive Days to Patients With Aneurysmal SAH Before and After Vascular Clipping</title>
        <description>Number of adverse events</description>
        <time_frame>First 10 days following clipping and 6 week F/U</time_frame>
        <population>Pilot Study- per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Procrit</title>
            <description>Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events After Administering Intravenous Doses of Procrit® Once Daily for Three Consecutive Days to Patients With Aneurysmal SAH Before and After Vascular Clipping</title>
          <description>Number of adverse events</description>
          <population>Pilot Study- per protocol</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine if Administration of Procrit® Prior to Aneurysm Clipping Reduces the Incidence of Vasospasm Following a SAH Event Treated by Vascular Clipping.</title>
        <time_frame>first 10 days following clipping and 6 week f/u</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine if Procrit® Administration Prior to Aneurysm Clipping in Patients With Aneurysmal SAH Will Improve Neurological Assessment Scores in the Post-SAH/Post-clipping Time Period</title>
        <time_frame>First 10 days following clipping and 6 week f/u</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Feasibility of Organizing a Larger, Randomized Study to Explore the Neuroprotective Effect of Procrit® in Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) When Procrit® is Administered Prior to Surgical Clipping of the Aneurysm.</title>
        <time_frame>When all data is collected and analyzed</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Procrit</title>
          <description>Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudo aneurysm left groin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In late October 2008, we received a letter from the sponsor requesting that we terminate any further work on this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Enrico M Camporesi MD</name_or_title>
      <organization>University of South Florida</organization>
      <phone>813-844-7170</phone>
      <email>ecampore@health.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

